Arvinas (ARVN) Cash from Operations (2017 - 2026)
Arvinas (ARVN) posted quarterly Cash from Operations of 69200000.0 for Q1 2026, up 22.16% year-over-year from 56647145.49 in Q1 2025, and down 127.63% quarter-over-quarter from 30400000.0 in Q4 2025.
Powered by 
Analysis
Arvinas (ARVN) Cash from Operations (2017 - 2026) Analysis & Trends
Arvinas' Cash from Operations history runs 10 years deep, the most recent figure standing at 69200000.0 for Q1 2026.
- In Q1 2026, Cash from Operations rose 22.16% year-over-year to 69200000.0; the TTM figure through Mar 2026 stood at 254100000.0 (down 1.36% YoY), while the FY2025 annual figure was 273800000.0, down 5.59% from the prior year.
- Cash from Operations for Q1 2026 stood at 69200000.0, down from 30400000.0 in the prior quarter.
- The five-year high for Cash from Operations was 50300000.0 in Q2 2024, with the low at 128000000.0 in Q3 2024.
- The 5-year median for Cash from Operations is 83100000.0 (2023), against an average of 71976470.59.
- The sharpest annual moves came in 2024 and 2025: Cash from Operations jumped 156.71% in 2024, then tumbled 289.66% in 2025.
- Arvinas' Cash from Operations stood at 71200000.0 in 2022, then retreated by 16.71% to 83100000.0 in 2023, then retreated by 1.2% to 84100000.0 in 2024, then jumped by 63.85% to 30400000.0 in 2025, then slumped by 127.63% to 69200000.0 in 2026.
- Business Quant data shows ARVN's Cash from Operations at 69200000.0 in Q1 2026, 30400000.0 in Q4 2025, and 59100000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Arvinas | 605.56 Mn | 37.66 Mn | - | -48.30 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -48.30 Mn |
| Mar 31, 2026 | -69.20 Mn |
| Dec 31, 2025 | -30.40 Mn |
| Sep 30, 2025 | -59.10 Mn |
| Jun 30, 2025 | -95.40 Mn |
| Mar 31, 2025 | -88.90 Mn |
| Dec 31, 2024 | -84.10 Mn |
| Sep 30, 2024 | -128.00 Mn |
| Jun 30, 2024 | 50.30 Mn |
| Mar 31, 2024 | -97.50 Mn |
| Dec 31, 2023 | -83.10 Mn |
| Sep 30, 2023 | -84.80 Mn |
| Jun 30, 2023 | -88.70 Mn |
| Mar 31, 2023 | -91.20 Mn |
| Dec 31, 2022 | -71.20 Mn |
| Sep 30, 2022 | -66.60 Mn |
| Jun 30, 2022 | -78.60 Mn |
| Mar 31, 2022 | -57.10 Mn |
| Dec 31, 2021 | -35.70 Mn |
| Sep 30, 2021 | 681.50 Mn |